Drug intelligence / Profile preview

Lu AF76432

Development stage: Phase 1
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Oral

Overview

Lu AF76432 is a small molecule drug developed by H. Lundbeck A/S that acts as a phosphodiesterase 1 (PDE1) inhibitor. It is being investigated primarily for the treatment of cognitive and behavioral problems, with the mechanism of action involving inhibition of PDE1 enzymes to enhance signaling between nerve cells in the brain. The drug has undergone Phase 1 clinical trials assessing safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy young men via single ascending oral doses. Its development status remains pending further clinical progress.

Targets

PDE1 (Phosphodiesterase 1)

Beyond the preview

Go deeper on Lu AF76432.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lu AF76432.

Explore the full profile